Shares of Forty Seven Inc. (FTSV) have been on a roll ever since the Company presented updated clinical data from its ongoing phase Ib trial evaluating Magrolimab in combination with Azacitidine for the treatment of myelodysplastic syndrome and acute myeloid leukemia last December.
from RTT - Biotech https://ift.tt/2NK3o1H
via IFTTT
No comments:
Post a Comment